

connection with the special elections must simultaneously file FEC Form 3L if they receive two or more bundled

contributions from lobbyists/registrants or lobbyist/registrant PACs that aggregate in excess of \$16,000 during

the special election reporting periods (see charts below for closing date of each period). 11 CFR 104.22(a)(5)(v).

CALENDAR OF REPORTING DATES FOR INDIANA SPECIAL ELECTION COMMITTEES INVOLVED IN THE SPECIAL GENERAL ELECTION (11/02/10) MUST FILE:

Report	Close of books <sup>1</sup>	Reg./Cert. & overnight mailing deadline	Filing deadline
Pre-General .....	10/13/10	10/18/10	10/21/10.
Post-General .....	11/22/10	12/02/10	12/02/10.
Year-End .....	12/31/10	01/31/11	01/31/11.

<sup>1</sup> The reporting period always begins the day after the closing date of the last report filed. If the committee is new and has not previously filed a report, the first report must cover all activity that occurred before the committee registered as a political committee with the Commission up through the close of books for the first report due.

Dated: June 11, 2010.

On behalf of the Commission.

**Matthew S. Petersen,**

*Chairman, Federal Election Commission.*

[FR Doc. 2010-14568 Filed 6-16-10; 8:45 am]

**BILLING CODE 6715-01-P**

## FEDERAL MARITIME COMMISSION

### Notice of Agreements Filed

The Commission hereby gives notice of the filing of the following agreements under the Shipping Act of 1984.

Interested parties may submit comments on the agreements to the Secretary, Federal Maritime Commission, Washington, DC 20573, within ten days of the date this notice appears in the **Federal Register**. Copies of the agreements are available through the Commission's Web site (<http://www.fmc.gov>) or by contacting the Office of Agreements at (202)-523-5793 or [tradeanalysis@fmc.gov](mailto:tradeanalysis@fmc.gov).

*Agreement No.:* 012100.

*Title:* CMA CGM/CSAV Gulf Bridge Express Vessel Sharing Agreement.

*Parties:* CMA CGM Antilles Guyane and Compania Sud American de Vapores S.A.

*Filing Party:* Draughn Arbona, Esq.; Associate Counsel & Environmental Officer; CMA CGM (America) LLC; 5701 Lake Wright Drive; Norfolk, VA 23502.

*Synopsis:* The agreement authorizes the parties to share vessel space in the trade between the U.S. Gulf coast and Mexico, Jamaica, Colombia, and Venezuela. The parties have requested expedited review.

*Agreement No.:* 012101.

*Title:* NYK/"K" Line/MOL Vessel Sharing Agreement.

*Parties:* Kawasaki Kisen Kaisha, Ltd.; Mitsui O.S.K. Lines, Ltd.; and Nippon Yusen Kaisha.

*Filing Party:* Wayne R. Rohde, Esq.; Sher & Blackwell LLP; 1850 M Street, NW., Suite 900; Washington, DC 20036.

*Synopsis:* The agreement authorizes the parties to share vessel space in the trade between Hawaii and ports in Japan, China, Korea, and Pacific Coasts of Mexico, Colombia, and Ecuador.

By Order of the Federal Maritime Commission.

Dated: June 14, 2010.

**Rachel E. Dickon,**

*Assistant Secretary.*

[FR Doc. 2010-14679 Filed 6-16-10; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Public Meeting of the Presidential Commission for the Study of Bioethical Issues

**AGENCY:** Department of Health and Human Services, Office of Public Health and Science, The Presidential Commission for the Study of Bioethical Issues.

**ACTION:** Notice.

**SUMMARY:** The Presidential Commission for the Study of Bioethical Issues (Amy Gutmann, PhD, Chair, and James Wagner, PhD, Vice Chair), will conduct its first meeting to discuss the implications of synthetic biology.

**DATES:** The meeting will take place Thursday, July 8, 2010, from 8:30 a.m. to 5 p.m., ET; and Friday, July 9, 2010, from 8:30 a.m. to 11:45 a.m., ET.

**ADDRESSES:** The Ritz-Carlton, 1150 22nd Street, NW., Washington, DC 20037. Phone 202-835-0500.

**FOR FURTHER INFORMATION CONTACT:** Ms. Diane M. Gianelli, Acting Executive Director, The Presidential Commission for the Study of Bioethical Issues, 1425 New York Avenue, NW., Suite C-100, Washington, DC 20005. Telephone: 202/233-3960. E-mail: [info@bioethics.gov](mailto:info@bioethics.gov). Web site: <http://www.bioethics.gov>.

**SUPPLEMENTARY INFORMATION:** The meeting agenda will be posted at <http://www.bioethics.gov>. The Commission encourages public comment, either in person or in writing. Interested members of the public may address the Commission at select times to be announced at the meeting. Comments are limited to no more than five minutes per speaker or organization. As a courtesy, please inform Ms. Diane M. Gianelli, Acting Executive Director, in advance, of your intention to make a public statement, and give your name and affiliation. To submit a written statement, mail or e-mail it to Ms. Gianelli at one of her contact addresses given above.

Dated: June 9, 2010.

**Diane M. Gianelli,**

*Acting Executive Director, The Presidential Commission for the Study of Bioethical Issues.*

[FR Doc. 2010-14577 Filed 6-16-10; 8:45 am]

**BILLING CODE 4154-06-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[60 Day-10-10ES]

### Proposed Data Collections Submitted for Public Comment and Recommendations

In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. Alternatively, to obtain a copy of the data collection plans and instrument, call 404-639-5960 and send comments to Maryam I. Daneshvar, CDC Reports Clearance Officer, 1600 Clifton Road,

NE., MS-D74, Atlanta, Georgia 30333; comments may also be sent by e-mail to [omb@cdc.gov](mailto:omb@cdc.gov).

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have a practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of information technology. Written comments should be received within 60 days of this notice.

**Proposed Project**

LRN Special Data Calls—Existing Collection in Use Without an OMB

Control Number—National Center for Emerging and Zoonotic Infectious Diseases (proposed) (NCEZID, Centers for Disease Control and Prevention (CDC).

*Background and Brief Description*

The Laboratory Response Network (LRN) was established by the Department of Health and Human Services, Centers for Disease Control and Prevention (CDC) in accordance with Presidential Decision Directive 39, which outlined national anti-terrorism policies and assigned specific missions to Federal departments and agencies. The LRN's mission is to maintain an integrated national and international network of laboratories that can respond to acts of biological, chemical, or radiological terrorism and other public health emergencies. Federal, state and

local public health laboratories voluntarily join the LRN.

The LRN Program Office maintains a database of information for each member laboratory that includes contact information as well as staff and equipment inventories. However, semiannually or during emergency response the LRN Program Office may conduct a Special Data Call to obtain additional information from LRN Member Laboratories in regards to biological or chemical terrorism preparedness. Special Data Calls may be conducted via queries that are distributed by broadcast emails or by survey tools (*i.e.* Survey Monkey). This is a request for a generic clearance. The only cost to respondents is their time to respond to the data call.

**Estimate of Annualized Burden Hours**

Forms	Number of respondents	Average number of responses per respondent	Average burden per response (hours)	Total burden hours
Special Data Call .....	200	4	30/60	400

Dated: June 10, 2010.

**Maryam I. Daneshvar,**

*Reports Clearance Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2010-14625 Filed 6-16-10; 8:45 am]

**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. FDA-2010-N-0279]

**Center for Drug Evaluation and Research Data Standards Plan; Availability for Comment**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability for public comment of the draft document entitled "CDER Data Standards Plan Version 1.0" (draft plan). The draft plan outlines the general approach proposed for development of a comprehensive data standards program in the Center for Drug Evaluation and Research (CDER). The draft plan identifies key objectives for a data standards program at CDER, processes to be developed to ensure successful use of those standardized data, and a set of recommended projects to begin in calendar year (CY) 2010.

**DATES:** Submit either electronic or written comments on the draft plan by September 15, 2010.

**ADDRESSES:** Submit written requests for single copies of the draft plan to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 2201, Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to assist that office in processing your requests. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the draft plan.

Submit electronic comments on the draft plan to <http://www.regulations.gov>. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

**FOR FURTHER INFORMATION CONTACT:** Ranjit Thomas, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 1166, Silver Spring, MD 20993-0002, e-mail: [Ranjit.Thomas@fda.hhs.gov](mailto:Ranjit.Thomas@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:**

**I. Background**

FDA receives an enormous and growing amount of data in regulatory submissions in a variety of formats from many sources. This wealth of data holds great potential to advance CDER's

regulatory and scientific work, but the present lack of standardized data creates significant challenges to realizing that potential. A data standards plan would enhance CDER's ability to efficiently and effectively perform its critical public health mission.

At present, the lack of standardized data affects CDER's review processes by curtailing a reviewer's ability to perform integral tasks such as rapid acquisition, analysis, storage, and reporting of regulatory data. Standardized data will allow reviewers to increase review consistency and perform evaluations across the drug lifecycle. Improved data quality, accessibility, and predictability will give reviewers more time to carry out complex analyses, ask in-depth questions, and address late-emerging issues.

Standardization of data submissions, a requirement for electronic submissions, and a robust computational infrastructure would make significant improvements possible. Facilitating improvements requires careful analysis, advanced planning, project management, expert input, and effective communication among all key stakeholders. To be successful, a plan is required to identify, develop, adopt, and maintain data standards that meet CDER "end user" needs.

FDA is making available for public comment the draft plan entitled "CDER